Literature DB >> 32229636

Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.

John Breitner1, Pierre-Francois Meyer1.   

Abstract

Entities:  

Year:  2020        PMID： 32229636     DOI： 10.1212/WNL.0000000000009185

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

Review 1.  Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Authors:  Awanish Mishra; Ritam Bandopadhyay; Prabhakar Kumar Singh; Pragya Shakti Mishra; Neha Sharma; Navneet Khurana
Journal:  Metab Brain Dis       Date:  2021-08-13       Impact factor: 3.584

2.  Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations.

Authors:  Olaf Stuve; Rick A Weideman; Danni M McMahan; David A Jacob; Bertis B Little
Journal:  Ther Adv Neurol Disord       Date:  2020-06-25       Impact factor: 6.570

Review 3.  Can We Treat Neuroinflammation in Alzheimer's Disease?

Authors:  Sandra Sánchez-Sarasúa; Iván Fernández-Pérez; Verónica Espinosa-Fernández; Ana María Sánchez-Pérez; Juan Carlos Ledesma
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

Review 4.  Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer's Disease.

Authors:  Maria Calvo-Rodriguez; Elizabeth K Kharitonova; Brian J Bacskai
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

Review 5.  Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands.

Authors:  Ferenc Bogár; Lívia Fülöp; Botond Penke
Journal:  Biomolecules       Date:  2022-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.